A new analysis of the U.S. Food and Drug Administration’s artificial intelligence-enabled medical device database details how the technology’s regulatory standing has evolved in recent years.
As the EU AI Act’s transparency requirements come into force, organizations need to be on the front foot when it comes to regulatory readiness and how AI is being used. Facing fines of up to €35 million or 7% of global turnover mean it’s no longer enough to just monitor communication risks. Firms must definitively…
